The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Legal
  • Sports

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
  • Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Warm, Dry Summer Forecast Points to a Stronger Wasp and Yellowjacket Season Across the Pacific Northwest
  • Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale
  • SafeBets Named Presenting Sponsor of IMCX 2026, Bringing Its No-Deposit Prediction Platform to the Creator Economy's Deal-Making Conference
  • Turnstone Creative's Ashley Russo Serves as Emcee for United Way's 2026 NERC and Women's Summit
  • A New Pulse for Cardiac Care in Baltimore: St. Elizabeth Rehab & Nursing Welcomes Dr. Hakim Uqdah and Expands Advanced Heart Program

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • Lighthouse 153 Brings Fresh Seafood, Craft Beer, and Coastal Charm to Downtown Hanover This Summer
  • Inframark–Slater Joint Venture Selected to Manage Fulton County Wastewater Operations
  • Cancun International Airport Reports Strong Start to Summer 2026 Travel Season
  • Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
  • GitKraken Introduces Code Flow, a Framework for Software Development in the Agentic Era

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
  • CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
  • Brilliant Minds to Gather in Fort Worth for National Mensa Event
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
  • Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
  • TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
  • Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
  • Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • What Would you Do with Your Time if it Was Actually Money?
  • Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
  • Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 176
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • SteelTree Announces Launch of Its Operational Decision Intelligence Service
  • Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption

Similar on PennZone

  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Dominican Fashion Designer Raiza Bonaparte presents the Sovereign Despampanante Collection at the Library of Congress
  • Roohid Parast on How AI Is Changing What Bench Scientists Can Do
  • Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale
  • A New Pulse for Cardiac Care in Baltimore: St. Elizabeth Rehab & Nursing Welcomes Dr. Hakim Uqdah and Expands Advanced Heart Program
  • Lighthouse 153 Brings Fresh Seafood, Craft Beer, and Coastal Charm to Downtown Hanover This Summer
  • Inframark–Slater Joint Venture Selected to Manage Fulton County Wastewater Operations
  • GitKraken Introduces Code Flow, a Framework for Software Development in the Agentic Era
  • RIGHT CARS Announces Landmark African Expansion Through Strategic Collaboration Agreement Across Eight Nations
  • purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us